Elevate Capital Advisors LLC acquired a new stake in shares of Chemed Co. (NYSE:CHE - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 2,087 shares of the company's stock, valued at approximately $1,106,000.
Other hedge funds have also added to or reduced their stakes in the company. HighTower Advisors LLC lifted its position in Chemed by 78.0% in the 3rd quarter. HighTower Advisors LLC now owns 3,730 shares of the company's stock valued at $2,246,000 after acquiring an additional 1,634 shares in the last quarter. XTX Topco Ltd raised its stake in shares of Chemed by 111.5% in the third quarter. XTX Topco Ltd now owns 2,843 shares of the company's stock worth $1,709,000 after purchasing an additional 1,499 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Chemed by 4.9% during the third quarter. Geode Capital Management LLC now owns 335,443 shares of the company's stock valued at $201,820,000 after purchasing an additional 15,791 shares in the last quarter. Signal Advisors Wealth LLC boosted its position in shares of Chemed by 60.7% during the fourth quarter. Signal Advisors Wealth LLC now owns 4,995 shares of the company's stock valued at $2,647,000 after buying an additional 1,886 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Chemed by 8.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 122,788 shares of the company's stock worth $73,792,000 after buying an additional 9,178 shares in the last quarter. 95.85% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the company's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $572.77, for a total value of $1,145,540.00. Following the completion of the sale, the chief executive officer now owns 101,735 shares in the company, valued at $58,270,755.95. This represents a 1.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Brian C. Judkins acquired 145 shares of the stock in a transaction dated Monday, December 30th. The shares were bought at an average cost of $519.50 per share, for a total transaction of $75,327.50. Following the completion of the transaction, the vice president now owns 1,678 shares in the company, valued at approximately $871,721. This represents a 9.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.32% of the company's stock.
Chemed Price Performance
Shares of CHE traded up $10.97 during trading hours on Thursday, hitting $560.47. The stock had a trading volume of 76,066 shares, compared to its average volume of 89,537. The firm has a market capitalization of $8.44 billion, a PE ratio of 28.32, a PEG ratio of 2.16 and a beta of 0.48. Chemed Co. has a 12 month low of $512.12 and a 12 month high of $654.62. The stock has a fifty day moving average price of $542.24 and a 200 day moving average price of $564.74.
Wall Street Analysts Forecast Growth
CHE has been the topic of several research analyst reports. Royal Bank of Canada lowered their target price on shares of Chemed from $697.00 to $633.00 and set an "outperform" rating on the stock in a research note on Tuesday, November 5th. StockNews.com upgraded shares of Chemed from a "hold" rating to a "buy" rating in a research report on Saturday, November 30th.
Read Our Latest Analysis on CHE
Chemed Company Profile
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Read More
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
